In an effort to improve the efficacy of antisense delivery, we evaluated polyethyleneimine (PEI, 2 kDa) alone or grafted with nonionic amphiphilic block copolymer Pluronic s (P85) as a carrier for Ku86 antisense oligonucleotide (ASO) delivery. Ku86 is an abundant nuclear protein that plays an important role in nonhomologous DNA end joining and has implications in tumorigenesis and acquired drug resistance. Transfection of adherent and suspension cell lines with Ku86 ASOs complexed with P85-g-PEI (2 kDa) conjugates was associated with a specific decrease in Ku86 mRNA levels (EC 50 o75 nM and EC 50 o250 nM, respectively, n ¼ 3). More importantly, no requirement for reduced serum conditions was necessary during transfection. In contrast, whereas Ku86 ASOs complexed with PEI (2 kDa) alone were effective in decreasing Ku86 mRNA levels in adherent cell lines (EC50o75 nM, n ¼ 3), the formulation did not produce any detectable decrease in Ku86 mRNA levels in suspension cell lines. Transfection of adherent cell lines with 500 nM Ku86 ASOs formulated with P85-g-PEI (2 kDa) was associated with a specific decrease (o10% remaining of control) in Ku86 protein expression and a two-fold increased cell death after treatment with ionizing radiation (IR). In athymic nude mice bearing subcutaneous human HT29 colon adenocarcinoma xenografts, Ku86 ASO-P85-g-PEI (2 kDa) administration (15 mg/kg, subcutaneously) with a Q1D Â 7 treatment schedule, when combined with a single dose of IR (6 Gy), caused a significant inhibition of HT29 tumor growth compared with mismatch-and naked antisense-pretreated control groups (time from 200 to 1000 mm 3 , 126.9 versus 84.18 and 87.76 days, Po0.005). A potentiation of the antitumor activity was observed in all mice treated with Ku86 ASO-P85-g-PEI (2 kDa) formulation; however, tumor growth inhibition was reversible upon treatment cessation. No morbidity/mortality or changes in histopathology were observed under this treatment regiment. Our results indicate that P85-g-PEI (2 kDa) conjugates may increase the efficacy of Ku86 ASO delivery in management of resistant malignancies, thus providing a rationale for their evaluation in cancer patients in combination with conventional anticancer therapies.
In an effort to improve the efficacy of antisense delivery, we evaluated polyethyleneimine (PEI, 2 kDa) alone or grafted with nonionic amphiphilic block copolymer Pluronic s (P85) as a carrier for Ku86 antisense oligonucleotide (ASO) delivery. Ku86 is an abundant nuclear protein that plays an important role in nonhomologous DNA end joining and has implications in tumorigenesis and acquired drug resistance. Transfection of adherent and suspension cell lines with Ku86 ASOs complexed with P85-g-PEI (2 kDa) conjugates was associated with a specific decrease in Ku86 mRNA levels (EC 50 o75 nM and EC 50 o250 nM, respectively, n ¼ 3). More importantly, no requirement for reduced serum conditions was necessary during transfection. In contrast, whereas Ku86 ASOs complexed with PEI (2 kDa) alone were effective in decreasing Ku86 mRNA levels in adherent cell lines (EC50o75 nM, n ¼ 3), the formulation did not produce any detectable decrease in Ku86 mRNA levels in suspension cell lines. Transfection of adherent cell lines with 500 nM Ku86 ASOs formulated with P85-g-PEI (2 kDa) was associated with a specific decrease (o10% remaining of control) in Ku86 protein expression and a two-fold increased cell death after treatment with ionizing radiation (IR). In athymic nude mice bearing subcutaneous human HT29 colon adenocarcinoma xenografts, Ku86 ASO-P85-g-PEI (2 kDa) administration (15 mg/kg, subcutaneously) with a Q1D Â 7 treatment schedule, when combined with a single dose of IR (6 Gy), caused a significant inhibition of HT29 tumor growth compared with mismatch-and naked antisense-pretreated control groups (time from 200 to 1000 mm 3 , 126.9 versus 84.18 and 87.76 days, Po0.005). A potentiation of the antitumor activity was observed in all mice treated with Ku86 ASO-P85-g-PEI (2 kDa) formulation; however, tumor growth inhibition was reversible upon treatment cessation. No morbidity/mortality or changes in histopathology were observed under this treatment regiment. Our results indicate that P85-g-PEI (2 kDa) conjugates may increase the efficacyIntroduction Antisense oligonucleotides (ASOs) have become promising candidates as therapeutic agents. However, an increasing body of evidence suggests that antisense nonspecific interactions, degradation, liver and renal uptake can significantly downgrade their performance following systemic administration. Among several cationic copolymers, polyethyleneimine (PEI) has been regarded as a useful carrier for in vitro and in vivo ASO delivery. 1 This polymer forms complexes with DNA as a result of cooperative electrostatic interactions between the amino groups of the polycation and phosphate groups of the DNA. Besides the high binding potency of PEI to DNA, its buffering properties provide facilitated release of the DNA-PEI complexes from endosomes (proton sponge effect). However, most polycations, including PEI, present a severe drawback since their complexes with DNA are often poorly soluble. In addition, systemic administration of the DNA-PEI complexes lead to microembolism in capillaries and significantly reduced bioavailability of DNA in target tissues. 2 A promising approach for overcoming the solubility problem has recently been proposed by several investigators. [3] [4] [5] [6] It uses a new type of cationic carrier with block copolymer architecture consisting of a polycation linked to a nonionic water-soluble polymer. The complexes formed between DNA and these cationic copolymers remain in dispersion due to the effect of the nonionic chains that are soluble in water.
In this work, we evaluated polyethyleneimine (PEI, 2 kDa) grafted with nonionic amphiphilic block copolymer, Pluronic s P85 (P85-g-PEI (2 kDa)) as a carrier for Ku86 ASO delivery. Ku86 plays an important role in a variety of cellular responses as a component of the DNAdependent protein kinase. Inactivating mutations of Ku86 gene results in hypersensitivity to ionizing radiation (IR) due to a defect in DNA double-strand break (DSB) repair. 7, 8 On the contrary, an increase in DNA DSB repair renders the cell less susceptible to DNA damage, and an increasing body of evidence suggests the contribution of DNA-dependent protein kinase (DNA-PK) to IR and anticancer drug resistance. 9 As such, it can be assumed that a transient downregulation of Ku86 gene expression, for example with highly specific ASOs, may have the potential of being used as a therapeutic approach in conjunction with conventional therapies in the treatment of human malignancies. To this end, employing 20-mer 2 0 -O-methoxyethyl/uniform phosphorothioate chimeric ASOs specifically targeted against human Ku86 mRNA, we have previously shown sensitization of malignant cells to IR and anticancer drugs. 10 The initial aim of the current study was to evaluate the efficacy of Ku86 ASO, formulated with PEI (2 kDa) and P85-g-PEI (2 kDa) conjugates, in downregulating Ku86 mRNA and protein levels in four adherent and two suspension cell lines. We also evaluated the possible use of Ku86 ASOs formulated with P85-g-PEI (2 kDa) conjugates as an in vivo radiosensitizing agent, by testing their ability to inhibit tumor growth in combination with IR in athymic nude mice bearing subcutaneous human HT29 colon adenocarcinoma xenografts. Using this animal model, we have shown that the combined use of the Ku86 ASO-P85-g-PEI (2 kDa) and IR is associated with a significant antitumor effect exhibited by delayed tumor development. Our results also suggest that P85-g-PEI (2 kDa) conjugates favor in vitro ASOs delivery in adherent and suspension cell lines, and have the potency of being used as an effective in vivo delivery vehicle.
Results

Preparation of polymer complexes
The ratio of the concentration of total nitrogen atoms (N) of PEI (2 kDa) and the P85-g-PEI (2 kDa) conjugate to that of the phosphate groups (P) of Ku86 ASOs was used as a characteristic of the complex composition. Complexes of Ku86 ASOs with cationic copolymers PEI (2 kDa) and P85-g-PEI (2 kDa) were prepared at various N/P ratios and analyzed by agarose gel electrophoresis. Movement of the Ku86 ASO-polymer complexes corresponded to the degree of negative charge neutralization by the polymers (data not shown). The complexes with N/P ratios o1 moved towards the anode, whereas the complexes with N/P 41 remained in the wells. Although the latter were presumably of some positive charge, the movement towards the cathode was not observed most likely due to the increased size of the complexes rendering them unable to enter 2% agarose gel within 30 min of electrophoresis. At an N/P ratio of 1:1, the complexes did migrate towards the anode, suggesting that some negative charge was still present.
Cell treatment and inhibition of Ku86 mRNA expression
In order to determine the optimal N/P ratio for Ku86 ASO delivery, the complexes were prepared at 1.67 mM oligonucleotide concentration and M059K, M059J, HT29, and MCF7 adherent cell lines were transfected in a complete growth medium supplemented with 10% FBS. After a 6-h incubation, a reduction in Ku86 steady-state mRNA levels was observed when Ku86 ASOs were formulated with both PEI (2 kDa) and P85-g-PEI (2 kDa) cationic copolymers (Figure 1a, b ; only MCF7 cells shown). However, the effect on a specific decrease in Ku86 mRNA levels was more pronounced at a broader N/P ratio range when Ku86 ASO was formulated with P85-g-PEI (N/P ratio from 1:5 to 20:1) compared to that of PEI (N/P ratio from 1:5 to 1:1) in all cell lines transfected. Next, we decided to determine a Ku86 ASO 50% effective concentration (EC 50 ) when it was complexed with cationic polymers PEI (2 kDa) or P85-g-PEI (2 kDa). As such, ASO-polymer complexes were prepared at the N/P ratio of 1:1, but oligonucleotide concentrations ranged from 50 to 800 nM in a 500 ml transfection volume. Four adherent (M059K, M059J, HT29, MCF7) and two suspension (WSU-CLL, K562) malignant cell lines were used in the study. The mismatch oligonucleotide was used as a control. After a 6-h incubation, a dose-dependent reduction of Ku86 steady-state mRNA levels was observed in all adherent cell lines transfected with Ku86 ASOs formulated with Figure 2a and b). Interestingly, whereas Ku86 ASOs complexes formed with P85-g-PEI (2 kDa) led to a significant reduction of Ku86 steady-state mRNA levels in both WSU-CLL and K562 suspension cell lines, the PEI (2 kDa) formulation was ineffective. Effective concentrations (50%) for all cell lines are presented in Figure 2c . One possible explanation for this difference emanates from poor solubility and significant aggregation of PEI (2 kDa)-ASO complexes. The complexes may precipitate over adherent cells, which still may result in Ku86 ASO transfection. However, the precipitates do not affect suspension cells and no reduction of Ku86 steadystate mRNA levels was observed in both WSU-CLL and K562 suspension cell lines. The results of this study indicate that treatment with Ku86 ASO in the presence of the P85-g-PEI (2 kDa) carrier leads to a substantial decrease in Ku86 steady-state mRNA level at low concentrations and in a dose-dependent manner in both adherent and suspension cell lines.
Inhibition of Ku86 protein expression with Ku86 ASO-P85-g-PEI (2 kDa) formulation
It was reported previously that the apparent half-life of Ku86 protein in the K562 cell line was 45 days. 11 However, in our previously published time-course experiment that followed a single Lipofectin-assisted Ku86 ASO transfection of M059K and M059J cells, it was shown that Ku86 protein level (detected by Western blot analysis) decreased to o10% remaining of the control level by 72 h. 10 In agreement with our previous observations, a single transfection with Ku86 ASO at 500 nM in the presence of the P85-g-PEI (2 kDa) carrier, N/P 10:1 and 1:1, led to a substantial decrease in Ku86 protein level ( Figure 3 ). In contrast, treatment of the cells with Ku86 ASO mismatch control formulated with the P85-g-PEI (2 kDa) carrier did not affect Ku86 protein levels.
In vitro sensitivity of Ku86 antisense-treated M059K and HT29 cells to IR
Colony survival assays were used to investigate the effect of Ku86 protein downregulation associated with antisense treatment on the sensitivity of M059K and HT29 cells to IR. Both cell lines were transfected two times for 6 h with 500 nM antisense or mismatch control Pluronic P85 enhances Ku86 antisense delivery AI Belenkov et al formulated with the P85-g-PEI (2 kDa) carrier within a 72-h interval. Treatment of M059K and HT29 cells with mismatch control did not confer any additional sensitivity to the radiation dose that produces 90% cytotoxicity (ID 90 ; 3.8 and 5.4 Gy, respectively), whereas treatment with antisense was associated with a two-fold potentiation of radiation sensitivity (ID 90 ; 2.1 and 2.8 Gy, respectively) (Figure 4a and b) . These findings are in agreement with our previous report of the radiosensitivity enhancement of Ku86 ASO-Lipofectin pretreated cells 10 and indicate that treatment of M059K and HT29 cells with Ku86 ASOs in the presence of the P85-g-PEI (2 kDa) carrier enhances radiosensitivity of the cells to the levels previously observed.
Ku86 antisense-P85-g-PEI (2 kDa) treatment in vivo
To examine the P85-g-PEI (2 kDa) system as an effective in vivo Ku86 ASO delivery vehicle, we used HT29 human colorectal adenocarcinoma cells as a transplantable xenograft model in immunodeficient mice. The model was characterized by a relatively good take rate of 90% and spontaneous regression of 0% with mean volumedoubling time of 9.070.6 days. 12 It is responsive to IR, but unresponsive to treatment with classical alkylating agents with a Q4D Â 3 treatment schedule in subcutaneous (s.c.) models (%T/C440). When exposed to girradiation from a 137 Cs source for time periods equivalent to 6 Gy, we observed a growth delay of 23.9 days when compared with nonirradiated controls (time from 200 to 1000 mm 3 , Po0.05), a %T/C value of 36.82%, which is considered borderline to inactive ( Figure 5 ). The formulations of the Ku86 ASO and its mismatch with the P85-g-PEI (2 kDa) carrier were prepared at the N/P ratio of 1:1. The formulations were administered s.c. (15 mg/kg) in a volume of 150 ml with a Q1D Â 7-treatment schedule starting on day 10 after the transplantation, when tumors reached approximately 60 mg (four mice in each group, two independent experiments). An additional group of tumor-bearing mice (four mice) was treated with naked Ku86 ASO (15 mg/kg, 150 ml s.c.) with the same treatment schedule. On day 15, the areas with tumors were exposed to g-irradiation from a 137 Cs source for time periods equivalent to 6 Gy. Tumor progression was monitored twice a week and the tumor size was measured in three dimensions. Ku86 ASO-P85-g-PEI (2 kDa) carrier treatment, when combined with a single dose of IR (6 Gy 
Examination of Ku86 protein level in HT29 xenografts
To further confirm that HT29 xenograft growth delay in animals after Ku86 ASO-P85-g-PEI (2 kDa) carrier treatment combined with IR was due to a specific Ku86 protein level decrease, we treated two animals with the Ku86 ASO and its mismatch formulated with the P85-g-PEI (2 kDa) carrier (15 mg/kg) in a volume of 150 ml with a Q1D Â 7-treatment schedule on day 10, when the transplants were approximately 60 mg. These animals were not treated with IR and the tumors were excised on day 16 and processed for protein extraction, as described in 'Materials and methods'. Protein extracts from the tumor excised from the antisense-treated animal showed a significant decrease in Ku86 protein levels (B37% of the nontreated control, detected by Western blot analysis). In contrast, treatment with Ku86 mismatch control did not affect Ku86 protein levels ( Figure 6 ), underlining the notion that the observed effect in tumor growth delay in the Ku86 antisense-treated mice was dependent on an antisense-specific mechanism.
Discussion
This work reports the evaluation of the cationic polymers, PEI (2 kDa) alone or grafted with nonionic amphiphilic block copolymer Pluronic s (P85) as carriers for Ku86 antisense delivery. Accumulating evidence suggests the implication of the Ku heterodimer in tumorigenesis and acquired drug resistance. 9,13-15 As a part of a DNA-PK complex, Ku86 is involved in DSB repair by non-homologous end joining (NHEJ) -a key determinant of IR resistance in mammalian cells. Whereas an overexpression of the Ku heterodimer in malignant cells leads to IR resistance, its loss confers IR sensitivity and increases homologous recombination (HR). NHEJ often results in imprecise repair, yielding insertions or deletions. HR, on the other hand, typically results in accurate repair. 9 Interestingly, when normal human fibroblasts were subjected to the treatment with wortmannin, a drug commonly used to modulate DNA-PK activity, there was no effect on DSB rejoining detected in the cells exposed to relatively low doses of IR. Alternatively, in A549 human lung carcinoma cells, this treatment strongly inhibited DSB rejoining, suggesting that tumor cells with uncontrolled cell growth and proliferation are more susceptible to the combined treatment than normal cells. 16, 17 As such, antisense approach that utilizes highly specific 2 0 -O-methoxyethyl/uniform phosphorothioate chimeric ASOs directed against Ku86 mRNA can be employed in combination with radiotherapy and/or chemotherapy to overcome drug resistance in several malignancies and possibly spare nonmalignant cells. 10 In order to downregulate gene expression, ASOs must penetrate the negatively charged cell membrane. Although a large number of experiments strongly suggest that the uptake of naked oligonucleotides do occur, the process is too low for a telling biological effect. 18 Moreover, it is important 1, 19 PEI is a product of the acid-catalyzed polymerization of aziridine and highly branched due to end-group reactions and high reactivity of the intermediate immonium species. PEI is very soluble in water and has a high capacity to charge electropositively. 1 To be efficient for transfection, PEI-DNA complexes must bear a net positive charge. In experiments where the luciferase gene expression was studied in 3T3 murine fibroblasts, it was found that luciferase expression was the highest in cells transfected with complexes containing approximately 10 PEI nitrogens per DNA phosphate (N/P ratio of 10). 1 However, a number of limitations are related to its use as a DNA delivery vehicle. Lower ratios were less efficient as a result of reduced cell-surface binding, whereas very high ratios (490) caused cytopathic effects. This toxic cellular response could be a consequence of the endo-lysosomal enzyme release into the cytoplasm as a result of excessive presence of membrane-disruptive PEI particles. 20 However, it seems that the transfection efficiency and toxicity of PEI correlated strongly with its molecular mass. For example, although less toxic, PEI (2 kDa) is some 2 orders of magnitude less efficient for gene delivery applications when compared with PEI (25 kDa). 21 Another limitation comes from the observation that PEI-DNA complexes are often poorly soluble. 6 A promising approach to overcome these problems has been recently proposed. 3, 6, 22 This approach utilizes grafting of the PEI molecule with nonionic water soluble polyethers, such as poly(ethylene oxide) (PEO) or PEO-bpoly(propylene oxide)-b-PEO block copolymers (Pluronics s ). The complexes formed between DNA and these cationic copolymers remain in dispersion due to the effect of nonionic chains that are soluble in water, which significantly reduces aggregation of PEI/DNA complexes and prolongs the circulation time of these complexes after systemic administration. Similarly, the results of the present work clearly show that, by modifying PEI with amphiphilic block copolymer Pluronic s (P85), Ku86 ASO-polycation complexes that are highly stable in aqueous dispersions can be obtained, even upon complete neutralization of charge. In addition to their stability, it is noteworthy that these complexes retained transfection ability in the presence of serum. This is an obvious improvement compared with the PEI homopolymers, which form with DNA either insoluble complexes or soluble complexes that are highly sensitive to the media composition. In our studies, the P85-modified PEI (2 kDa) has also revealed consistently high transfection activity in both adherent and suspension cell lines tested. P85 belongs to a class of polymeric surfactants, which possess the ability to interact with biological membranes and enhance transport of many biologically active compounds into the cell. Pluronic and similar block copolymers are known to form a core-shelllike structure alone and when combined with various types of compounds. 23 Therefore, overall bioavailability and safety of these ASO formulations may become significantly improved, allowing their systemic administration. Overall, the results of this study suggest that the P85-g-PEI (2 kDa)-based transfection system can be efficient not only for in vitro, but also for in vivo Ku86 ASO delivery.
Materials and methods
Cell lines and culture
Human EBV WSU-CLL cells were kindly provided by Dr Ramzi M Mohammad (Wayne State University School of Medicine, Detroit, MI, USA). K562 was obtained from the American Type Culture Collection (Rockville, MD, USA). Both suspension cell lines were maintained in RPMI 1640 (Life Technologies, Inc., Burlington, Ontario, Canada) supplemented with 10% (v/v) FBS (Life Technologies, Inc.). M059K, M059J, MCF7, and HT29 cells were obtained from American Type Culture Collection (Rockville, MD, USA) and cultured in DMEM (Life Technologies, Inc.) supplemented with 10% (v/v) FBS. All cell lines were maintained in a humidified atmosphere of 5% CO 2 at 371C.
Oligonucleotides and cationic copolymers
Ku86 2
0 -O-methoxyethyl/uniform phosphorothioate chimeric ASOs, targeted to human Ku86 mRNA, were synthesized and kindly provided by ISIS Pharmaceuticals, Inc. (Carlsbad, CA, USA). PEI (MW 2000) was purchased from Sigma-Aldrich (St Louis, MO, USA). P85-g-PEI (2 kDa) was synthesized, purified, and kindly provided by Supratek Pharma Inc. (Dorval, Quebec). Briefly, 20% of free terminal hydroxyl groups of Pluronic s P85 were activated by the reaction with 1,1 0 -carbonyldiimidazole in anhydrous acetonitrile for 4 h at 201C. The reaction of the activated copolymer with equimolar quantity of branched PEI, MW 2000, was carried out in 20% ethanol for 48 h at 201C. The conjugate was purified from admixture of free PEI by gelpermeation chromatography on the column with Sephadex G-25 using 20% ethanol as eluent. Fractions containing the conjugate and free PEI were analyzed by color reaction with ninhydrine. The fraction separated on the Sephadex G-25 column consisted of the mixture of the P85-g-PEI (2 kDa) conjugate (20%) and free Pluronic s P85 (80%). The total nitrogen content in the mixture was 1 mmol/mg, as determined by elemental microanalysis. Since the final formulation of ASO with P85-g-PEI (2 kDa) required the presence of the free Pluronic s P85, the conjugate was not purified from the admixture of the unconjugated block copolymer and the mixture was used for preparing ASO formulation.
Agarose gel electrophoresis
Complexes of ASO with PEI (2 kDa) or P85-g-PEI (2 kDa) were obtained by direct mixing of the solutions of both components to obtain the desired N/P ratio. Briefly, 6 mg of Ku86 ASOs (2 mg/ml) was combined with 1, 2, 4, 8, 16, and 32 ml of 1% solution (10 mg/ml) of the P85-g-PEI (2 kDa) conjugate to obtain 1:10, 1:5, 1:1, 5:1, 10:1, and 20:1 N/P ratios. Ku86 ASOs complexed with P85-g-PEI (2 kDa) conjugates at different N/P ratios were analyzed by electrophoresis on a 2% agarose gel with 0.04 M Trisacetate buffer, pH 7.4, at 100 V for 30 min. Oligonucleotides were visualized by UV illumination following staining of the gel with ethidium bromide (0.5 mg/ml) for 20 min.
Complexes of cationic copolymers with ASOs and cell treatment
For the treatment, nonadherent WSU-CLL and K562 cells were mixed with oligonucleotides combined with a carrier at the desired N/P ratios and concentrations in RPMI 1640 supplemented with 10% FBS at 5.0 Â 10 5 cells/ml for 6 h. Adherent M059K, M059J, MCF7, and HT29 cells were seeded onto 12-well plates (Falcon; Becton Dickinson Labware, Lincoln Park, NJ, USA). When 70-80% confluent, the cells were washed once with PBS and exposed to antisense and mismatch oligonucleotides combined with a carrier at desired N/P ratios and concentrations in complete growth medium supplemented with 10% FBS for 6 h. After transfection, cells were washed once with PBS to remove the transfection solution and when needed incubated in complete medium for additional time intervals. Lipofectin solution (Life Technologies, Inc.) was used at a final concentration of 3 mg/ml.
Extraction of total RNA
Total RNA was extracted using the RNeasy Mini kit (Qiagen, Santa Clarita, CA, USA) according to the manufacturer's methods. Extracted total RNA was treated with DNase enzyme in a DNA digestion mixture (10 ml of 100 mM MgCl 2 , 10 mM DTT 1 ml of RNasin (Promega, Madison, WI, USA), and 1 ml of RNase-free DNase 20 U/ml (Promega)) for 15 min at 371C. After DNase treatment, samples were extracted once with phenol-chloroform-isoamyl alcohol and chloroformisoamyl alcohol, and precipitated with ethanol at À701C. RNA concentration and purity were determined by measuring absorbances at 260 and 280 nm. The integrity of the samples was assessed by running 1 mg of RNA on a nondenaturing 1% agarose gel.
Semiquantitative RT-PCR
To quantitate Ku86 mRNA expression in antisensetreated and control cells, 1 mg of DNase-treated total RNA was used for first-strand cDNA synthesis, as described previously. 10 The Ku86 PCR primers were 5 0 -CAG CCG ATT CAG CAA AAG TC-3 0 (forward) and 5 0 -TCA TCC AAC CCA TCT TCA CC-3 0 (reverse), with a predicted product size of 250 nucleotides. H3.3 histone was used as a housekeeping gene 24 and PCR primers were 5 0 -GTA AAG CAC CCA GGA AGC AA-3 0 (forward) and 5 0 -ACG CTG GAA GGG AAG TTT G-3 0 (reverse), with a predicted product size of 170 nucleotides. PCR was carried out in a total volume of 50 ml containing 5 ml of 10 Â PCR buffer (500 mM KCl, 15 mM MgCl 2 , and 100 mM Tris-HCl, pH 9.0 (Amersham Pharmacia Biotech)), 2. 
Preparation of whole-cell extracts
Whole-cell extracts were prepared by a single freezethaw cycle, as described. 25 Briefly, cells were harvested, washed with ice-cold PBS and LSB (25 mM KCl, 10 mM NaCl, 1 mM MgCl 2 , 10 mM HEPES-KOH (pH 7.2), 0.1 mM EDTA, 2 mg/ml leupeptin (Sigma Chemical Co., St Louis, MO, USA), 2 mg/ml aprotinin (Sigma), 0.5 mM DTT, 0.5 mM phenylmethylsulfonyl fluoride), repelleted, and resuspended in LSB to a final volume of 2.5 times the original packed cell volume. Resuspended cells were incubated on ice for 10 min, frozen by plunging into liquid nitrogen, quickly placed at 371C until slightly thawed, and then placed on ice. NaCl and MgCl 2 concentrations of fully thawed samples were adjusted to 0.5 and 10 mM, respectively, by adding HSB (5 M NaCl, 100 mM MgCl 2 , and 5 mM DTT). Cell extracts were incubated on ice for 5 min and microcentrifuged at 10 000 g for 5 min at 41C. Supernatants were collected, and protein concentrations were quantitated using the method of Bradford.
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Immunoblotting Cell extracts containing 10-50 mg of protein were separated by SDS-PAGE and transferred electrophoretically onto nitrocellulose membranes (Millipore, Bedford, MA, USA) for 1 h in 25 mM Tris-HCl, 192 mM glycine, and 20% methanol. Membranes were blocked in TBS (Tris-HCl) containing 5% nonfat milk and probed with anti-Ku86 (111), and a-tubulin monoclonal antibodies (NeoMarkers, CA, USA). Antigen/antibody complexes were detected by horseradish peroxidase-conjugated antimouse antibody and enhanced chemiluminescence (Amersham Pharmacia Biotech), according to the manufacturer's instructions. The bands were quantified by densitometric analysis using Scion Image software (Scion Corp., Frederick, MD, USA).
Clonogenic survival assays
For treatment with IR, adherent cell lines were transfected additionally 72 h after the initiation of the first transfection for 6 h with Ku86 antisense or its mismatch control in the presence of the P85-g-PEI (2 kDa) conjugate (N/P ratio of 1:1). At the end of the second transfection, cells were trypsinized and replated onto 25-cm 2 tissue culture flasks (Sarstedt, Newton, NC, USA) at various concentrations (200-15 000 cells/well). After the cells were allowed to adhere to the bottom of the tissue culture flasks, they were exposed to g-irradiation from a 137 Cs source for time periods equivalent to 1.0, 2.0, 4.0, 6.0, 8.0, and 10.0 Gy. On day 14, cells were washed with PBS, fixed with glutaraldehyde, and stained with 1% crystal violet. Washed dishes were dried, and colonies containing 450 cells were scored and plotted on a log scale against drug concentration as a fraction of control.
Establishment of subcutaneous xenografts and treatment
Female BALB/c athymic mice (5-6 weeks of age) were purchased from Charles River Laboratories (St Constant, Quebec, Canada). All experiments were conducted in accordance with the guidelines for the care and use of laboratory animals. 1.0 Â 10 7 HT29 colon adenocarcinoma cells were implanted s.c. into each of three animals. The implants were made s.c. in a volume of 500 ml on Pluronic P85 enhances Ku86 antisense delivery AI Belenkov et al lateral flanks using a 25-gauge needle. No more than 30 min elapsed from the time tumors were removed from donor animals. The animals were palpated twice weekly for tumor appearance. When developed, the tumors were transplanted s.c. on lateral flanks in 30-40 mg fragments using 13-gauge trocar needles for antisense/ mismatch+IR treatment. The formulations of the Ku86 ASO and its mismatch with P85-g-PEI (2 kDa) conjugates (N/P ratio of 1:1) were administered s.c. (15 mg/kg) in a volume of 150 ml with a Q1D Â 7-treatment schedule on day 10 after the transplantation when tumors reached approximately 60 mg. On day 15, the areas with tumors were exposed to g-irradiation from a 137 Cs source for time periods equivalent to 6 Gy. Tumor progression was monitored twice a week and the tumor size was measured in three dimensions. The tumor volume was calculated using the formula: length(mm) Â width(mm) Â height(mm)/2 Â p/3 ¼ mm 3 .
Calculation of optimal %T/C and tumor growth delay
Median tumor volume and days to attain a specific size (1000 mm 3 ) were calculated from the nonlinear curve fitting (Origin, Microcal Software, Inc., MA, USA). Optimal %T/C represents changes in tumor weight for each treated (T) and control (C) group, and was calculated from the median tumor weights on the specific observation day (eg when nontreated controls attained a volume of 1000 mm 3 ). A percent tumor growth delay is expressed as a percentage by which the treated group weight is delayed in attaining a specified number of doublings compared to controls, using the formula: [(T-C)/C] Â 100, where T and C are the median times in days for treated and control groups, respectively, to attain the specified size.
